CytoCell IVD FISH probes for acute lymphoblastic leukaemia diagnosis

Want to download this as a PDF? Download now

ALLTogether1 – A treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL) – Laboratory Study Protocol Guidelines

EU Clinical Trials Register EudraCT number 2018-001795-38

CHIEF INVESTIGATOR: MD PhD Mats Marshall Heyman, Karolinska University Hospital, Sweden

Introduction

The primary objective of ALLTogether1 is to improve survival and quality of life in children and young adults with ALL. A sub-group of patients that may benefit from novel immunotherapy could be identified. The recruitment started in 2021 and will continue until at least May 2027.

The main treatment for ALL is chemotherapy, with a variety of drugs prescribed in different combinations, depending on the patient enrolled. Chemotherapy usually works well for children and young adults with ALL.

However, a better patient risk stratification would improve treatment plans and oncological outcomes, meaning less chemotherapy and reduced toxicity to patients in the low-risk group. The trial uses a combination of several factors to stratify patients into risk groups, determining the treatment they shall receive. This process includes investigating the cytogenetic abnormalities in leukaemic cells.<^1,2

Figure 1. Acute lymphoblastic leukaemia FISH test algorithm

Table 1. CytoCell^® IVD products that support the ALLTogether1 genetic risk stratification algorithm protocol implementation

Table 2. Other CytoCell probes and CytoCell myProbes^®, custom FISH probes that may aid in ALL research

References

1. EU Clinical Trials Register. Identifier 2018-001795-38, ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL). Available at: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001795-38 (Accessed August 2024).
2. ClinicalTrials.gov. Identifier NCT00287391, ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL). Available at: https://clinicaltrials.gov/study/NCT04307576 (Accessed August 2024).

Disclaimer

myProbes: For Research Use Only; Not for Use in Diagnostic Procedures. CytoCell: Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representatives for availability.